Prof Isabelle Ray-Coquard presents data from the PAOLA-1/ENGOT-ov25 trial during a press conference at the 2019 ESMO congress.
This was a phase III randomised trial which looked at the maintenance combined targeted therapy of PARP inhibitor olaparib added to bevacizumab, in patients with and without a BRCA mutation.
Watch Prof Isabelle Ray-Coquard's interview with ecancer here.
Watch Dr Susana Banerjee's comment here.
Read more about the study here.